Standard disclaimer: Im a physician, but Im not your physician
Court Decision Prevents Compounders from Producing Knockoffs of Novo Nordisks Semaglutide Grand View Research, UK GLP-1 Receptor Agonist Market Harvard University, GLP-1 Diabetes and Weight Loss Drug Side Effects: Ozempic Face and More Diabetes.org, How Many People in the UK Have Diabetes? CDC, National Diabetes Statistics Report WHO, Obesity and Overweight Health.com, Think GLP-1s Guarantee Weight Loss
Novo Nordisks CEO, Lars Fruergaard Jrgensen, raised the alarm, underscoring the risks of compounded semaglutide preparations, which may not adhere to the same rigorous safety standards as commercially manufactured versions
Their high surface area-to-volume ratio facilitates controlled and sustained drug release
Why Proper Administration is Important To get the full benefits of semaglutide, its essential to follow proper administration guidelines